Paper Details

  1. Home
  2. Paper Details

Platelet P2Y12 receptor inhibition by thienopyridines: status and future.

Author: BiasucciLuigi Marzio, CreaFilippo, De MariaGiovanni Luigi, GiubilatoSimona, PortoItalo

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Thienopyridines are effective in treating coronary artery disease, especially in acute coronary syndromes and percutaneous coronary interventions. Ticlopidine, the first FDA-approved thienopyridine, was effective in reducing coronary events in high-risk patients but had serious bone marrow toxicity. Clopidogrel, a second-generation thienopyridine, has fewer side effects and is as effective as ticlopidine. Clopidogrel, when combined with a low dose of aspirin, reduces the risk of major cardiovascular events in acute coronary syndrome patients. However, clopidogrel has a delayed onset of action and "resistance" is a concern. Prasugrel, a third-generation thienopyridine, has lower inter-patient response variability and a reduced incidence of ischemic events but increases the risk of major bleeding. New direct P2Y12 receptor antagonists, such as cangrelor and AZD6140, are being tested and have a faster reversal of platelet inhibition.
Paper Details　
Original Abstract of the Article :
Thienopyridines have a well-established role in the treatment of coronary artery disease, especially in the setting of acute coronary syndromes and percutaneous coronary interventions. Ticlopidine, the first FDA-approved thienopyridine, was shown to be effective in reducing coronary events in high r...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1517/13543780903176415

データ提供：米国国立医学図書館（NLM）

Thienopyridines: A Journey Through Platelet Inhibition

Coronary artery disease (CAD), a major health concern affecting millions worldwide, requires effective therapies to manage its debilitating effects. Imagine a caravan traversing a desert landscape, facing the challenge of navigating treacherous terrain. Thienopyridines, a class of drugs that inhibit platelet aggregation, are like skilled guides, helping to navigate the complex pathways of CAD treatment. This review examines the evolution of thienopyridines, from the first-generation drug ticlopidine to the newer, third-generation agents like prasugrel. The authors discuss the efficacy of these drugs in reducing cardiovascular events, highlighting the challenges associated with clopidogrel resistance and the emergence of novel, faster-acting P2Y12 receptor antagonists.

Navigating the Desert of Platelet Inhibition

This review provides a valuable roadmap for understanding the evolution of thienopyridines and their role in managing CAD. The authors discuss the challenges and successes associated with different generations of these drugs, highlighting the ongoing quest for more effective and safer therapies. This research serves as a valuable resource for healthcare professionals seeking to optimize treatment strategies for their patients with CAD.

The Future of CAD Treatment: A Horizon of Hope

The field of cardiovascular medicine is continuously evolving, with new therapies and approaches emerging to improve patient outcomes. This review highlights the ongoing advancements in platelet inhibition, offering hope for more effective and personalized treatments for CAD. It underscores the importance of staying abreast of the latest developments in cardiovascular medicine to provide the best possible care for patients.

Dr.Camel's Conclusion

The desert of CAD treatment is vast and complex, but the development of thienopyridines offers a beacon of hope for those seeking to navigate this challenging terrain. This review provides valuable insights into the evolution of these drugs, highlighting both their successes and limitations. By continuing to explore new pathways and refine our understanding of platelet inhibition, we can pave the way for a more effective and safer future for patients with CAD.

Date :
  1. Date Completed 2010-02-25
  2. Date Revised 2010-11-18
Further Info :

Pubmed ID

19678800

DOI: Digital Object Identifier

10.1517/13543780903176415

Related Literature

Article Analysis
・Side Effects of prasugrel
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.